GEN Exclusives

More »

GEN News Highlights

More »
Oct 17, 2006

Agreement Potentially Worth $530-M Reached by Roche and InterMune

  • Roche will exclusively license InterMune’s lead candidate compound, ITMN-191, according to a collaboration agreement between the two firms. The companies will also collaborate on a research program to identify, develop, and commercialize second-generation HCV protease inhibitors.

    InterMune will conduct Phase I studies on ITMN-191, expected to start at the end of 2006. Thereafter, Roche will lead clinical development and commercialization.

    Upon closing, InterMune will receive from Roche an upfront payment of $60 million. In addition, assuming the successful development and commercialization of ITMN-191 in the U.S. and other countries, InterMune could potentially receive up to $470 million in milestones, including $35 million within the next 12 months.

    Roche will fund 67% of the global development costs for ITMN-191 and the companies will co-commercialize the product in the U.S. and share profits on a 50-50 basis. InterMune will receive royalties outside the U.S. The economic terms for ITMN-191 could also apply to additional compounds that InterMune and Roche develop and commercialize.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?